RBA, located in Staten Island, New York, was founded by Drs. Mark DiBuono and Adam Smith. It has been conducting clinical trials for more than 14 years across a broad range of illnesses including depression, anxiety disorders, schizophrenia, bipolar disorder, cognitive impairment, Alzheimer’s and autism.
Andria Chastain, chief operating officer at ERG, said the addition of RBA to the ERG portfolio expands its footprint in New York.
“The opportunity for growth and expansion in our geographic region is undeniable and, given ERG’s excellent reputation in the industry and their proven track record of growing portfolio sites, our investigators, Dr. DiBuono and Dr. Eli Shalenberg, firmly believe that ERG is the perfect partner to take our site to the next level,” Smith said.
Honigman LLP and Kirkland & Ellis LLP served as legal advisors to ERG. Nixon Peabody served as legal advisors to RBA.
“Dr. DiBuono and Dr. Smith have built a high-quality organization that fits perfectly with ERG. RBA’s thoughtful growth plan aligns with ERG’s vision for the future, allowing us to further service our deep client base and continue to assist in the development of important new therapies,” Michael Farah, chairman of ERG and partner at Linden Capital Partners, said.